CFO of SOPHiA Genetics Buys 20,000 Shares, Signaling Confidence After Strategic Sloan Kettering Deal

Insider Buying Signals a Confidence Upswing

On June 5th, CFO Carlo Georgi “George” Car‑doza purchased 20,000 ordinary shares of SOPHiA Genetics at $4.95 per share—just one cent below the closing price of $4.96 on June 3rd. The trade, made in an open‑trading window, is the first buying move by Car‑doza in over two months after a series of sales earlier in April. The purchase comes amid a broader investor conversation about the company’s newly announced partnership with Memorial Sloan Kettering, which promises a precision‑medicine hub that could unlock significant revenue streams from AI‑driven diagnostics.

A Shift from Selling to Accumulating

Car‑doza’s transaction history paints a picture of a cautious but ultimately bullish stance. In April, he sold 2,520 shares at $4.85, then 2,413 shares at $4.88, and 1,403 shares at $4.85. These sales left him with 291,458 shares—an average cost basis of roughly $4.86. The recent purchase brings his holdings to 311,458 shares, raising his average price slightly to $4.89. The move is notable because it follows a period of intense selling across senior management—chief medical officer, president, and executive officer all sold thousands of shares in late May. Car‑doza’s decision to buy rather than sell signals a belief that the stock is undervalued relative to the company’s strategic trajectory.

Implications for Investors

For investors, the CFO’s buy is a positive catalyst. It suggests that the person most familiar with the company’s financials and pipeline is confident that the stock will rebound as the MOU with Sloan Kettering translates into tangible revenue and valuation gains. The market has already priced in the partnership, reflected in the company’s 52‑week high of $5.70 and a year‑to‑date gain of nearly 75%. The recent sell‑pressure from other executives has dampened momentum, but the CFO’s accumulation hints that insiders are now looking forward rather than reacting to short‑term volatility.

Car‑doza George: A Profile of Prudence and Patience

Car‑doza has been with SOPHiA since its early public days, rising through finance roles to CFO in 2024. Over the past year, his insider activity has been measured: he has bought more shares than he has sold (total buy of 164,671 shares in April versus 6,336 shares sold in April). He has also exercised a large option package (164,671 shares) in early April, indicating a willingness to commit capital when he believes the company’s fundamentals are sound. Historically, his trades have trended upward in price, reflecting an increasing confidence as the company’s market cap grows toward $343 million and its AI platform expands into oncology. Unlike some peers who sell aggressively during market dips, Car‑doza’s pattern shows a long‑term horizon: he retains a sizable stake and only divests when he needs liquidity or to balance his portfolio.

Looking Ahead

The CFO’s purchase, set against a backdrop of strategic partnerships and a resilient pipeline, suggests that insiders see a path to higher earnings and potentially a positive earnings surprise in 2027 as the precision‑medicine hub begins generating revenue. For the broader market, the signal is one of cautious optimism: insiders are buying, the company’s fundamentals are solid, and the AI‑driven healthcare sector is gaining traction. Investors should monitor the upcoming quarterly earnings for evidence of the partnership’s impact, while keeping an eye on any future insider trades that could confirm or contradict this bullish outlook.